SG11201912267SA - Nicotinamide riboside derivatives and their uses - Google Patents
Nicotinamide riboside derivatives and their usesInfo
- Publication number
- SG11201912267SA SG11201912267SA SG11201912267SA SG11201912267SA SG11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA SG 11201912267S A SG11201912267S A SG 11201912267SA
- Authority
- SG
- Singapore
- Prior art keywords
- nicotinamide riboside
- riboside derivatives
- derivatives
- nicotinamide
- riboside
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762521717P | 2017-06-19 | 2017-06-19 | |
PCT/US2018/038201 WO2018236814A2 (fr) | 2017-06-19 | 2018-06-19 | Dérivés de nicotinamide riboside et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201912267SA true SG11201912267SA (en) | 2020-01-30 |
Family
ID=62875307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201912267SA SG11201912267SA (en) | 2017-06-19 | 2018-06-19 | Nicotinamide riboside derivatives and their uses |
Country Status (4)
Country | Link |
---|---|
US (1) | US11286274B2 (fr) |
EP (1) | EP3642214A2 (fr) |
SG (1) | SG11201912267SA (fr) |
WO (1) | WO2018236814A2 (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018237383A1 (fr) * | 2017-06-23 | 2018-12-27 | The Trustees Of Columbia University In The City Of New York | Procédés de prévention et de traitement de maladies caractérisées par un dysfonctionnement synaptique et une neurodégénérescence, y compris la maladie d'alzheimer |
US20200261483A1 (en) * | 2017-10-30 | 2020-08-20 | Elysium Health, Inc. | Methods and compositions for treating cystic fibrosis |
WO2019108875A1 (fr) * | 2017-12-01 | 2019-06-06 | Elysium Health, Inc. | Méthodes et compositions pour le traitement du glaucome |
CN108841781A (zh) * | 2018-06-13 | 2018-11-20 | 延边大学 | 藏红花素在提高猪卵母细胞抗氧化能力及卵裂率中的应用 |
EP3897666A2 (fr) | 2018-12-17 | 2021-10-27 | Mitopower LLC | Composés nicotinyl riboside et leurs utilisations |
US11266696B2 (en) * | 2019-01-18 | 2022-03-08 | Americord Registry Llc | Method of treating stem cells with NAD |
CN109674808A (zh) * | 2019-01-30 | 2019-04-26 | 四川大学 | β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途 |
JP2022524930A (ja) * | 2019-02-26 | 2022-05-11 | ウニベルシタット デ バレンシア―エストゥディ ジェネラル | 運動ニューロン疾患を処置するための方法及び組成物 |
WO2020190703A1 (fr) * | 2019-03-21 | 2020-09-24 | Elysium Health, Inc. | Méthodes pour le traitement de plaies |
US20220125814A1 (en) * | 2019-03-21 | 2022-04-28 | Fred Hutchinson Cancer Research Center | Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor |
AU2020286602A1 (en) * | 2019-06-05 | 2021-11-11 | Société des Produits Nestlé S.A. | Reduced nicotinamideribosides for treating or preventing kidney disease |
CN113840612A (zh) * | 2019-06-05 | 2021-12-24 | 雀巢产品有限公司 | 用于治疗/预防肝脏疾病的还原型烟酰胺核糖核苷 |
JP2022534863A (ja) * | 2019-06-05 | 2022-08-04 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 骨格筋の疾患を治療/予防するための還元型ニコチンアミドリボシド |
EP3986420A1 (fr) * | 2019-06-18 | 2022-04-27 | Mitopower LLC | Composés nicotinyl riboside et leurs utilisations |
CA3145870A1 (fr) * | 2019-07-26 | 2021-02-04 | Hampar L. Karageozian | Peptides pour le traitement de la degenerescence maculaire non-exsudative et d'autres troubles de l'?il |
FR3102058A1 (fr) * | 2019-10-18 | 2021-04-23 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes |
CA3158767A1 (fr) * | 2019-10-30 | 2021-05-06 | Perfuse Therapeutics, Inc. | Traitement de maladies oculaires a l'aide d'antagonistes du recepteur de l'endotheline |
CN113490676A (zh) * | 2019-11-19 | 2021-10-08 | 清华大学 | Nmn衍生物的合成方法和nmn及其衍生物的医学应用 |
JP2023512763A (ja) | 2020-02-06 | 2023-03-29 | パフューズ セラピューティクス, インコーポレイテッド | 眼疾患の処置のための組成物 |
KR20220151628A (ko) * | 2020-03-06 | 2022-11-15 | 알레그로 파마슈티칼스, 엘엘씨 | 미토콘드리아 기능의 손상을 개선하거나 감소시키기 위한 치료 |
EP4117679A1 (fr) * | 2020-03-09 | 2023-01-18 | Société des Produits Nestlé S.A. | Compositions et procédés contenant du nicotinamide riboside réduit pour la prévention et le traitement d'infections virales et bactériennes |
EP4117681A1 (fr) * | 2020-03-09 | 2023-01-18 | Société des Produits Nestlé S.A. | Compositions contenant un nicotinamide riboside et méthodes destinées à la prévention et au traitement des maladies et affections pancréatiques |
FR3108502B1 (fr) * | 2020-03-27 | 2022-09-23 | Nuvamid Sa | Dérivés de nicotinamide mononucléotides dans le traitement et la prévention des infections bactériennes |
CN111454311B (zh) | 2020-04-03 | 2021-10-19 | 深圳市迪克曼科技开发有限公司 | 烟酰胺核糖的有机酸盐及其组合物与制备方法 |
US20210353656A1 (en) * | 2020-05-12 | 2021-11-18 | Nuvamid Sa | Combination of nicotinamide mononucleotide derivatives and histamine h2 receptor antagonists for viral infections |
EP3949964A1 (fr) * | 2020-08-06 | 2022-02-09 | Nuvamid SA | Combinaison de dérivés de nicotinamide mononucléotidique et d'autres agents thérapeutiques pour leur utilisation dans le traitement des infections virales |
WO2022029275A1 (fr) * | 2020-08-06 | 2022-02-10 | Nuvamid Sa | Combinaison de dérivés de nicotinamide mononucléotide et d'autres agents thérapeutiques destinée à être utilisée dans le traitement d'infections à coronavirus et de la covid-19 |
CN112500445B (zh) * | 2020-12-04 | 2022-11-29 | 黄冈鲁班药业股份有限公司 | β-烟酰胺核糖的制备方法 |
CN113274363B (zh) * | 2021-04-29 | 2023-02-10 | 珠海润都制药股份有限公司 | 一种吲达帕胺制剂 |
KR20240004643A (ko) | 2021-04-30 | 2024-01-11 | 퍼퓨즈 세라퓨틱스, 인크. | 안구 질환의 치료를 위한 제약 조성물 및 유리체내 약물 전달 시스템 |
EP4313067A1 (fr) * | 2021-06-18 | 2024-02-07 | Mitopower LLC | Traitement de troubles liés à l?immunité, de troubles rénaux, de troubles hépatiques, de troubles hémolytiques et de troubles liés au stress oxydatif à l'aide de nrh, narh et de leurs dérivés réduits |
WO2022269064A1 (fr) * | 2021-06-24 | 2022-12-29 | Vestlandets Innovasjonsselskap As (Vis) | Traitement d'augmentation de nad pour la maladie de parkinson |
AU2022401717A1 (en) * | 2021-12-01 | 2024-05-23 | University Of Florida Research Foundation, Incorporated | Combinatorial therapeutic approach for friedreich's ataxia |
CN115232184A (zh) * | 2021-12-06 | 2022-10-25 | 宁波熙健医药科技有限公司 | 呋喃核糖基吡啶衍生物及其药物组合物和用途 |
WO2024050120A2 (fr) * | 2022-09-02 | 2024-03-07 | The Regents Of The University Of California | Combinaisons de nicotinamide-riboside et de ptérostilbène pour traiter l'arthrose |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1190079A (en) | 1966-07-29 | 1970-04-29 | Kyowa Hakko Kogyo Company Ltd | Process for producing Nicotinamide Adenine Dinucleotide |
US6589948B1 (en) | 2000-11-28 | 2003-07-08 | Eukarion, Inc. | Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
WO2005009510A2 (fr) | 2003-07-23 | 2005-02-03 | The Regents Of The University Of California | Combinaisons d'amplificateurs de penetration pour administration transdermique |
EP1723227A4 (fr) | 2004-02-10 | 2007-09-19 | Dartmouth College | Compositions de nicotinamide riboside kinase et procedes d'utilisation |
EP1877054A2 (fr) | 2005-03-30 | 2008-01-16 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside et analogues |
US20070099830A1 (en) * | 2005-04-21 | 2007-05-03 | Massachusetts Institute Of Technology | Sirt4 activities |
US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
DK1957086T3 (en) | 2005-11-18 | 2018-06-06 | Cornell Res Foundation Inc | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE |
JP2011518200A (ja) | 2008-04-22 | 2011-06-23 | メルク フロスト カナダ リミテツド | ステアロイル−補酵素aデルタ−9デサチュラーゼの阻害剤としての新規な置換複素環式芳香族化合物 |
CA2725481A1 (fr) | 2008-06-18 | 2009-12-23 | Pfizer Limited | Derives de nicotinamide |
WO2012114204A2 (fr) * | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Procédés de traitement d'une dysfonction mitochondriale |
MX2015011195A (es) | 2013-03-15 | 2016-03-11 | Nusirt Sciences Inc | La leucina y el acido nicotinico reducen los niveles de lipidos. |
GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
EP3063163B1 (fr) | 2013-10-30 | 2022-08-10 | Chromadex Inc. | Compositions de nicotinamide riboside à usage topique pour traiter les affections cutanées |
EP3149016A1 (fr) | 2014-06-02 | 2017-04-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Préparation et utilisation de bêta-d-nicotinamide riboside cristallin |
JP6559713B2 (ja) * | 2014-06-06 | 2019-08-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | ニコチンアミドリボシド類似体ならびにその医薬組成物および使用 |
CN106715454B (zh) | 2014-07-24 | 2020-06-16 | 格雷斯公司 | 烟酰胺核苷的结晶形式 |
WO2016122832A1 (fr) | 2015-01-30 | 2016-08-04 | Natural Formulations | Compositions, méthodes thérapeutiques et prophylactiques pour le traitement de maladies neurodégénératives et de lésions cérébrales |
AU2016229319B2 (en) | 2015-03-09 | 2020-05-07 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
CA2979057C (fr) | 2015-03-16 | 2023-01-24 | ChromaDex Inc. | Compositions d'acide nicotinique riboside ou de nicotinamide riboside, derives reduits de ceux-ci, et utilisation de ceux-ci |
AU2016271481A1 (en) | 2015-06-04 | 2017-12-14 | Chromadex, Inc. | Selective solvent free phosphorylation |
US10392414B2 (en) * | 2015-07-15 | 2019-08-27 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
JP6949002B6 (ja) | 2015-08-05 | 2021-11-17 | メトロ インターナショナル バイオテック,エルエルシー | ニコチンアミドモノヌクレオチド誘導体及びそれらの使用 |
RU2768936C2 (ru) | 2015-10-07 | 2022-03-25 | Джоэль УЙСЕНГА | Нормализация функций биологических путей для защиты от и устранения нарушений, возникающих вследствие старения человека |
US10611790B2 (en) * | 2015-11-02 | 2020-04-07 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
AU2016375177B2 (en) | 2015-12-24 | 2022-09-01 | Amazentis Sa | Compositions comprising nicotinamide riboside and a urolithin |
WO2017161165A1 (fr) * | 2016-03-16 | 2017-09-21 | ChromaDex Inc. | Conjugués de vitamine b et d'acides aminés de ribosides de nicotinoyle et de ribosides de nicotinoyle réduits, dérivés de ceux-ci, et leurs procédés de préparation |
MX2018012527A (es) | 2016-04-14 | 2019-08-21 | Chromadex Inc | Uso de ribosido de nicotinamida, ribosido de acido nicotinico, mononucleotido de nicotinamida y derivados de compuestos nicotinoílo en formula para lactantes. |
KR20190008246A (ko) | 2016-04-20 | 2019-01-23 | 크로마덱스 아이엔씨. | Nad+ 증가용 전구체로서 니코틴산 리보사이드 또는 니코틴아미드 리보사이트 유도체 및 이의 환원된 유도체의 용도 |
WO2017218580A1 (fr) | 2016-06-14 | 2017-12-21 | Rejuvenation Therapeutics Corporation | Procédés synthétiques pour la préparation de nicotinamide riboside et de composés apparentés |
WO2018002215A1 (fr) | 2016-06-30 | 2018-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement de cardiomyopathies |
GB2553001A (en) | 2016-08-19 | 2018-02-21 | The Queen's Univ Of Belfast | Lactone intermediates of nicotinamide riboside and nicotinate riboside |
MX2019002211A (es) | 2016-08-22 | 2019-10-30 | Elysium Health Inc | Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos. |
CA3045876A1 (fr) | 2016-11-11 | 2018-05-17 | The Queen's University Of Belfast | Syntheses evolutives de nicotinoyle ribosides et de nicotin oyle ribosides reduits, de leurs derives modifies, de leurs analogues phosphoryles, de leurs conjugues avec de l'adenylyle dinucleotide et de nouvelles formes cristallines de ceux-ci |
US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
CA3044814A1 (fr) | 2016-11-29 | 2018-06-07 | Charles M. Brenner | Utilisation de precurseurs de nad pour ameliorer la sante maternelle et/ou la sante de la descendance |
US11389468B2 (en) | 2017-03-17 | 2022-07-19 | Elysium Health, Inc. | Nicotinamide riboside for use in treating or preventing liver damage |
-
2018
- 2018-06-19 EP EP18740009.8A patent/EP3642214A2/fr active Pending
- 2018-06-19 US US16/012,004 patent/US11286274B2/en active Active
- 2018-06-19 WO PCT/US2018/038201 patent/WO2018236814A2/fr unknown
- 2018-06-19 SG SG11201912267SA patent/SG11201912267SA/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018236814A2 (fr) | 2018-12-27 |
EP3642214A2 (fr) | 2020-04-29 |
US20180362570A1 (en) | 2018-12-20 |
US11286274B2 (en) | 2022-03-29 |
WO2018236814A3 (fr) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201912267SA (en) | Nicotinamide riboside derivatives and their uses | |
ZA201801196B (en) | Nicotinamide mononucleotide derivatives and their uses | |
ZA201808131B (en) | Amide-substituted pyridinyltriazole derivatives and uses thereof | |
HK1248240A1 (zh) | 烟酸核苷或烟酰胺核苷組合物、其還原衍生物及其用途 | |
HK1254654A1 (zh) | 4,6-亞嘧啶基衍生物及其用途 | |
IL253656A0 (en) | Mono- and polyazanephthalene modified histories and their use | |
EP3268362A4 (fr) | Pyridines substituées et leurs utilisations | |
HK1246156B (zh) | Fgf21衍生物及其用途 | |
HK1250164A1 (zh) | 苯胺嘧啶衍生物及其用途 | |
IL273839A (en) | Benzimidazole derivatives and their uses | |
HK1251226A1 (zh) | 吡啶和嘧啶衍生物 | |
GB2577419B (en) | Lipo-glycopeptide cleavable derivatives and uses thereof | |
EP3526215A4 (fr) | Dérivés de n-acyléthanolamide et leurs utilisations | |
LT3487851T (lt) | Aminopiridino dariniai ir jų naudojimas kaip selektyvių alk-2 inhibitorių | |
SG11202008543RA (en) | Pyrrolidineamide derivatives and uses thereof | |
EP3383401A4 (fr) | Dérivés de thiéno-pyrimidine et utilisations de ceux-ci | |
IL274722A (en) | History of pyridinones and their use as selective inhibitors of ALK-2 | |
EP3556764A4 (fr) | Dérivé de nucléoside et utilisation associée | |
EP3712160A4 (fr) | Dérivé de nucléoside et utilisation associée |